免疫检查点抑制剂毒性反应影像评估新进展
摘要
已经得到评估和应用，可以显著提升患者的生存率。ICI通过增强细胞免疫，提高宿主的抗肿瘤免疫力，同时也伴随
着免疫相关不良事件（irAEs）的出现。irAEs的早期诊断对于正确和快速地管理患者至关重要，掌握其的影像学表现
是及时排除其他诊断的关键。同时，在影像学新技术领域对irAEs的评估也不断取得新进展。本综述根据受累器官的
不同，对主要irAEs影像学表现和鉴别诊断进行了总结，并对新技术的发展进行展望。
关键词
全文:
PDF参考
[1]MALLIO C A, BERNETTI C, CEA L, et al.Adverse Effects of Immune-Checkpoint Inhibitors: A
Comprehensive Imaging-Oriented Review [J]. Curr Oncol,
2023, 30(5): 4700-23.
[2]MARTINS F, SOFIYA L, SYKIOTIS G P, et
al. Adverse effects of immune-checkpoint inhibitors:
epidemiology, management and surveillance [J]. Nat Rev Clin
Oncol, 2019, 16(9): 563-80.
[3]ABDEL-RAHMAN O, ELHALAWANI H,
FOUAD M. Risk of endocrine complications in cancer
patients treated with immune check point inhibitors: a metaanalysis [J]. Future Oncol, 2016, 12(3): 413-25.
[4]CASTILLERO F, CASTILLO-FERNáNDEZ O,
JIMéNEZ-JIMéNEZ G, et al. Cancer immunotherapyassociated hypophysitis [J]. Future Oncol, 2019, 15(27):
3159-69.
[5]SPAGNOLO C C, CAMPO I, CAMPENNì
A, et al. Challenges and pitfalls in the management of
endocrine toxicities from immune checkpoint inhibitors: a
case presentation of synchronous thyrotoxicosis and primary
adrenal insufficiency in a melanoma patient [J]. Hormones
(Athens), 2024.
[6]MIKAMI T, LIAW B, ASADA M, et al.
Neuroimmunological adverse events associated with immune
checkpoint inhibitor: a retrospective, pharmacovigilance study
using FAERS database [J]. J Neurooncol, 2021, 152(1): 135-
44.
[7]PARK H, HATABU H, RICCIUTI B, et al.
Immune-related adverse events on body CT in patients with
small-cell lung cancer treated with immune-checkpoint
inhibitors [J]. Eur J Radiol, 2020, 132: 109275.
[8]刘晓雯，龚静山，彭永佳，et al.免疫检查点抑制
剂相关不良反应影像评估[J].放射学实践，2023，38（07）：
952-6.
[9]朱燕，龚艳君，吴世凯.免疫检查点抑制剂相关
心脏毒性反应的研究进展[J].临床肿瘤学杂志，2021，26
（04）：373-9.
[10]BARINA A R, BASHIR M R, HOWARD B A,
et al. Isolated recto-sigmoid colitis: a new imaging pattern of
ipilimumab-associated colitis [J]. Abdom Radiol (NY), 2016,
41(2): 207-14.
[11]CHATTERJEE A, BIVAS B K, GEHANI A,
et al. Pembrolizumab-induced large duct cholangiopathy:
Diagnosis and follow.up imaging [J]. J Postgrad Med, 2021,
67(1): 43-5.
[12]HIRASAWA Y, YOSHIMURA K, MATSUI H,
et al. A case report on severe nivolumab-induced adverse
events similar to primary sclerosing cholangitis refractory to
immunosuppressive therapy [J]. Medicine (Baltimore), 2021,
100(23): e25774.
[13]PORCU M, SOLINAS C, MIGALI C, et al.
Immune Checkpoint Inhibitor-Induced Pancreatic Injury:
Imaging Findings and Literature Review [J]. Target Oncol,
2020, 15(1): 25-35.
[14]LIU J, SHI Y, LIU X, et al. Clinical characteristics
and outcomes of immune checkpoint inhibitor-induced
diabetes mellitus [J]. Transl Oncol, 2022, 24: 101473.
[15]ANDERSON M A, KHAULI M A, FURTADO F,
et al. Immunotherapy-related renal toxicity causes reversible
renal enlargement [J]. Abdom Radiol (NY), 2022, 47(9):
3301-7.
[16]LAU D, CORRIE P G, GALLAGHER F A. MRI
techniques for immunotherapy monitoring [J]. J Immunother
Cancer, 2022, 10(9).
[17]WU M, ZHANG Y, ZHANG Y, et al. Imagingbased Biomarkers for Predicting and Evaluating Cancer
Immunotherapy Response [J]. Radiol Imaging Cancer, 2019,
1(2): e190031.
[18]LARIMER B M. PET Imaging for Monitoring
Cellular and Immunotherapy of Cancer [J]. Cancer J, 2024,
30(3): 153-8.
[19]刘佳林，张皓.人工智能和影像组学在免疫检查
点抑制剂治疗非小细胞肺癌中的应用进展[J].临床肺科杂
志，2024，29（03）：434-8.
[20]COLEN R R, FUJII T, BILEN M A, et al.
Radiomics to predict immunotherapy-induced pneumonitis:
proof of concept [J]. Invest New Drugs, 2018, 36(4): 601-7.
[21]CHEN X, SHEIKH K, NAKAJIMA E, et al.
Radiation Versus Immune Checkpoint Inhibitor Associated
Pneumonitis: Distinct Radiologic Morphologies [J].
Oncologist, 2021, 26(10): e1822-e32.
Refbacks
- 当前没有refback。
